Literature DB >> 1482323

Adsorption of nafamostat mesilate by hemodialysis membranes.

O Inagaki1, Y Nishian, R Iwaki, K Nakagawa, Y Takamitsu, Y Fujita.   

Abstract

The adsorption of the anticoagulant nafamostat mesilate (FUT-175) by five different hemodialysis membranes was studied in vivo and in vitro. In vivo, FUT-175 was adsorbed strongly by a polyacrylonitrile (AN69) membrane and slightly by another polyacrylonitrile (J-PAN) membrane but not by Cuprophan (CU), hemophan (HE), or polymethylmethacrylate (PMMA) membranes during hemodialysis performed in 4 patients in whom FUT-175 was used as an anticoagulant. Only during hemodialysis using the AN69 membrane did FUT-175 not induce a significant prolongation of celite-activated coagulation time. In vitro studies showed that FUT-175 was adsorbed by the AN69, J-PAN, and PMMA membranes but not by the CU and HE membranes. Methylene blue, a dye that possesses a cationic portion in its chemical structure, stained AN69, J-PAN, and PMMA membranes. Since FUT-175 also possesses a cationic portion, we conclude that FUT-175 is adsorbed by negatively charged membranes via an ionic bond and is unsuited for use as an anticoagulant in hemodialysis using an AN69 membrane because of that membrane's marked capacity to adsorb FUT-175.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1482323     DOI: 10.1111/j.1525-1594.1992.tb00551.x

Source DB:  PubMed          Journal:  Artif Organs        ISSN: 0160-564X            Impact factor:   3.094


  4 in total

1.  Continuous renal replacement therapy in neonates weighing less than 3 kg.

Authors:  Young Bae Sohn; Kyung Hoon Paik; Hee Yeon Cho; Su Jin Kim; Sung Won Park; Eun Sun Kim; Yun Sil Chang; Won-Soon Park; Yoon-Ho Choi; Dong-Kyu Jin
Journal:  Korean J Pediatr       Date:  2012-08-23

2.  Role of citrate and other methods of anticoagulation in patients with severe liver failure requiring continuous renal replacement therapy.

Authors:  Josée Bouchard; François Madore
Journal:  NDT Plus       Date:  2008-12-09

3.  Efficacy and safety of nafamostat mesilate anticoagulation in blood purification treatment of critically ill patients: a systematic review and meta-analysis.

Authors:  Yao Lin; Yiming Shao; Yuchun Liu; Ruoxuan Yang; Shuanglin Liao; Shuai Yang; Mingwei Xu; Junbing He
Journal:  Ren Fail       Date:  2022-12       Impact factor: 3.222

4.  AN69ST membranes adsorb nafamostat mesylate and affect the management of anticoagulant therapy: a retrospective study.

Authors:  Takahiro Hirayama; Nobuyuki Nosaka; Yasumasa Okawa; Soichiro Ushio; Yoshihisa Kitamura; Toshiaki Sendo; Toyomu Ugawa; Atsunori Nakao
Journal:  J Intensive Care       Date:  2017-07-18
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.